ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine

NCT05656508 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Vaccine

Interventions

BIOLOGICAL: ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)

Sponsor

Laboratorio Pablo Cassara S.R.L.

Collaborators

[object Object]
[object Object]